Proline-rich Akt substrate of 40kDa (PRAS40): a novel downstream target of PI3k/Akt signaling pathway.

Modifications in signaling of the proline-rich Akt substrate of 40-kDa (PRAS40) pathway is implicated in type 2 diabetes and melanoma. PRAS40 is known for its ability to regulate the mammalian target of rapamycin complex 1 (mTORC1) kinase activity, possessing a key regulatory role at the cross point of signal transduction pathways activated by growth factor receptors. Recently it has been found that PRAS40 is regulated by its upstream phosphatidylinositol 3-kinase/Akt (PI3K/Akt) which is activated by many tyrosine kinase receptors growth factors including insulin-like growth factor 1. Also, PRAS40 functions downstream of mTORC1 and upstream from its effectors ribosomal protein S6 kinase 1 (S6K1) and eukaryotic initiation factor 4E binding protein 1 (4E-BP1). Phosphorylation of PRAS40 by Akt and mTORC1 disrupts the binding between mTORC1 and PRAS40, and relieves the inhibitory constraint of PRAS40 on mTORC1 activity. This review summarizes the signaling regulating PRAS40 phosphorylation, as well as the dual function of PRAS40 as substrate and inhibitor of mTORC1 upon growth factor stimulation and under pathophysiological conditions.

[1]  S. Kane,et al.  A Method to Identify Serine Kinase Substrates , 2002, The Journal of Biological Chemistry.

[2]  Wenhua Zheng,et al.  FKHRL1 and its homologs are new targets of nerve growth factor Trk receptor signaling , 2002, Journal of neurochemistry.

[3]  M. Birnbaum,et al.  Akt1/PKBα Is Required for Normal Growth but Dispensable for Maintenance of Glucose Homeostasis in Mice* , 2001, The Journal of Biological Chemistry.

[4]  J. Zierath,et al.  Insulin Receptor Substrate-1 Phosphorylation and Phosphatidylinositol 3-Kinase Activity in Skeletal Muscle From NIDDM Subjects After In Vivo Insulin Stimulation , 1997, Diabetes.

[5]  C. MacKintosh,et al.  Regulation of the 14-3-3-binding protein p39 by growth factors and nutrients in rat PC12 pheochromocytoma cells. , 2002, The Biochemical journal.

[6]  D. Sabatini.  mTOR and cancer: insights into a complex relationship , 2006, Nature Reviews Cancer.

[7]  Chin-Lee Wu,et al.  Insulin Stimulates Adipogenesis through the Akt-TSC2-mTORC1 Pathway , 2009, PloS one.

[8]  R. Quirion,et al.  Insulin-like Growth Factor-1-induced Phosphorylation of the Forkhead Family Transcription Factor FKHRL1 Is Mediated by Akt Kinase in PC12 Cells* , 2000, The Journal of Biological Chemistry.

[9]  S. Masters,et al.  Survival-promoting functions of 14-3-3 proteins. , 2001, Biochemical Society transactions.

[10]  S. Kane,et al.  Insulin-stimulated phosphorylation of the Akt substrate AS160 is impaired in skeletal muscle of type 2 diabetic subjects. , 2005, Diabetes.

[11]  Lewis C. Cantley,et al.  AKT/PKB Signaling: Navigating Downstream , 2007, Cell.

[12]  C. Lang,et al.  PRAS40 Regulates Protein Synthesis and Cell Cycle in C2C12 Myoblasts , 2010, Molecular medicine.

[13]  J. Gusella,et al.  NF2/Merlin Is a Novel Negative Regulator of mTOR Complex 1, and Activation of mTORC1 Is Associated with Meningioma and Schwannoma Growth , 2009, Molecular and Cellular Biology.

[14]  S. Huh,et al.  Targeting Akt3 Signaling in Malignant Melanoma Using Isoselenocyanates , 2009, Clinical Cancer Research.

[15]  G. Mills,et al.  Activation of murine double minute 2 by Akt in mammary epithelium delays mammary involution and accelerates mammary tumorigenesis. , 2010, Cancer research.

[16]  X. Lu,et al.  Overexpression of osteopontin induces angiogenesis of endothelial progenitor cells via the avβ3/PI3K/AKT/eNOS/NO signaling pathway in glioma cells. , 2011, European journal of cell biology.

[17]  G. Dohm,et al.  Insulin activation of phosphatidylinositol 3-kinase in human skeletal muscle in vivo. , 1997, Journal of applied physiology.

[18]  C. Proud,et al.  PRAS40 Is a Target for Mammalian Target of Rapamycin Complex 1 and Is Required for Signaling Downstream of This Complex* , 2007, Journal of Biological Chemistry.

[19]  G. Thomas,et al.  mTOR Complex1-S6K1 signaling: at the crossroads of obesity, diabetes and cancer. , 2007, Trends in molecular medicine.

[20]  W. Sessa,et al.  Targeting of Endothelial Nitric-oxide Synthase to the Cytoplasmic Face of the Golgi Complex or Plasma Membrane Regulates Akt- Versus Calcium-dependent Mechanisms for Nitric Oxide Release* , 2004, Journal of Biological Chemistry.

[21]  R. Roth,et al.  PRAS40 Regulates mTORC1 Kinase Activity by Functioning as a Direct Inhibitor of Substrate Binding* , 2007, Journal of Biological Chemistry.

[22]  A. Gomez-Muñoz,et al.  Activation of mTOR and RhoA is a major mechanism by which Ceramide 1-phosphate stimulates macrophage proliferation. , 2011, Cellular signalling.

[23]  J. Javitch,et al.  Roles of the Akt/GSK-3 and Wnt signaling pathways in schizophrenia and antipsychotic drug action. , 2010, The American journal of psychiatry.

[24]  K. Maiese,et al.  Activating Akt and the brain's resources to drive cellular survival and prevent inflammatory injury. , 2005, Histology and histopathology.

[25]  G. Ruvkun,et al.  Phosphatidylinositol 3-Kinase Signaling Inhibits DAF-16 DNA Binding and Function via 14-3-3-dependent and 14-3-3-independent Pathways* , 2001, The Journal of Biological Chemistry.

[26]  Joe W. Gray,et al.  PIK3CA is implicated as an oncogene in ovarian cancer , 1999, Nature Genetics.

[27]  Lewis C Cantley,et al.  The phosphoinositide 3-kinase pathway. , 2002, Science.

[28]  J. Avruch,et al.  Raptor, a Binding Partner of Target of Rapamycin (TOR), Mediates TOR Action , 2002, Cell.

[29]  H. Pijl,et al.  Loss of 50% of excess weight using a very low energy diet improves insulin-stimulated glucose disposal and skeletal muscle insulin signalling in obese insulin-treated type 2 diabetic patients , 2007, Diabetologia.

[30]  J. Eckel,et al.  Insulin-Mediated Phosphorylation of the Proline-Rich Akt Substrate PRAS40 Is Impaired in Insulin Target Tissues of High-Fat Diet–Fed Rats , 2006, Diabetes.

[31]  D. Alessi,et al.  TSC1–TSC2: a complex tale of PKB-mediated S6K regulation , 2002, Nature Cell Biology.

[32]  K. Kaestner,et al.  Insulin Resistance and a Diabetes Mellitus-Like Syndrome in Mice Lacking the Protein Kinase Akt2 (PKBβ) , 2001 .

[33]  D. Ouwens,et al.  Phosphorylation of PRAS40 on Thr246 by PKB/AKT facilitates efficient phosphorylation of Ser183 by mTORC1. , 2010, Cellular signalling.

[34]  S. Nagata,et al.  A caspase-activated DNase that degrades DNA during apoptosis, and its inhibitor ICAD , 1998, Nature.

[35]  C. Lang,et al.  Alcohol and PRAS40 knockdown decrease mTOR activity and protein synthesis via AMPK signaling and changes in mTORC1 interaction , 2010, Journal of cellular biochemistry.

[36]  John M Asara,et al.  Insulin-stimulated Phosphorylation of a Rab GTPase-activating Protein Regulates GLUT4 Translocation* , 2003, The Journal of Biological Chemistry.

[37]  M. Birnbaum,et al.  Construction and Characterization of a Conditionally Active Version of the Serine/Threonine Kinase Akt* , 1998, The Journal of Biological Chemistry.

[38]  J. Zierath,et al.  Characterization of signal transduction and glucose transport in skeletal muscle from type 2 diabetic patients. , 2000, Diabetes.

[39]  Gavin W. Porter,et al.  Expression of proline-rich Akt-substrate PRAS40 in cell survival pathway and carcinogenesis , 2005, Acta Pharmacologica Sinica.

[40]  A. Nakashima,et al.  The Proline-rich Akt Substrate of 40 kDa (PRAS40) Is a Physiological Substrate of Mammalian Target of Rapamycin Complex 1* , 2007, Journal of Biological Chemistry.

[41]  A. V. D. van den Ouweland,et al.  Identification and Characterization of the Interaction between Tuberin and 14-3-3ζ* , 2002, The Journal of Biological Chemistry.

[42]  R. Roth,et al.  On the Mechanism for Neomycin Reversal of Wortmannin Inhibition of Insulin Stimulation of Glucose Uptake* , 2004, Journal of Biological Chemistry.

[43]  J. Testa,et al.  A Portrait of AKT Kinases: Human Cancer and Animal Models Depict a Family with Strong Individualities , 2004, Cancer biology & therapy.

[44]  S. Kropf,et al.  Different Activation of Mitogen-Activated Protein Kinase and Akt Signaling Is Associated with Aggressive Phenotype of Human Meningiomas , 2005, Clinical Cancer Research.

[45]  A. Newton,et al.  PHLPP: a phosphatase that directly dephosphorylates Akt, promotes apoptosis, and suppresses tumor growth. , 2005, Molecular cell.

[46]  W. Aird,et al.  The Akt-regulated Forkhead Transcription Factor FOXO3a Controls Endothelial Cell Viability through Modulation of the Caspase-8 Inhibitor FLIP* , 2004, Journal of Biological Chemistry.

[47]  T. McGraw,et al.  Insulin stimulation of GLUT4 exocytosis, but not its inhibition of endocytosis, is dependent on RabGAP AS160. , 2004, Molecular biology of the cell.

[48]  J E Paciga,et al.  AKT1/PKBalpha kinase is frequently elevated in human cancers and its constitutive activation is required for oncogenic transformation in NIH3T3 cells. , 2001, The American journal of pathology.

[49]  Michael B Yaffe,et al.  How do 14‐3‐3 proteins work? – Gatekeeper phosphorylation and the molecular anvil hypothesis , 2002, FEBS letters.

[50]  Timothy J. Griffin,et al.  Insulin signalling to mTOR mediated by the Akt/PKB substrate PRAS40 , 2007, Nature Cell Biology.

[51]  P. Graves,et al.  14-3-3 Proteins Are Required for Maintenance of Raf-1 Phosphorylation and Kinase Activity , 1998, Molecular and Cellular Biology.

[52]  A. Saito,et al.  Increased Expression of a Proline-Rich Akt Substrate (PRAS40) in Human Copper/Zinc-Superoxide Dismutase Transgenic Rats Protects Motor Neurons from Death after Spinal Cord Injury , 2008, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[53]  K. M. Nicholson,et al.  The protein kinase B/Akt signalling pathway in human malignancy. , 2002, Cellular signalling.

[54]  I. Roninson,et al.  Growth retardation and increased apoptosis in mice with homozygous disruption of the Akt1 gene. , 2001, Genes & development.

[55]  J. Avruch,et al.  14-3-3 Proteins: Active Cofactors in Cellular Regulation by Serine/Threonine Phosphorylation* , 2002, The Journal of Biological Chemistry.

[56]  N. Sonenberg,et al.  mTOR, translation initiation and cancer , 2006, Oncogene.

[57]  P. Dennis,et al.  Akt/protein kinase B is constitutively active in non-small cell lung cancer cells and promotes cellular survival and resistance to chemotherapy and radiation. , 2001, Cancer research.

[58]  Hui-yu Liu,et al.  Regulation of Interleukin-6-induced Hepatic Insulin Resistance by Mammalian Target of Rapamycin through the STAT3-SOCS3 Pathway* , 2008, Journal of Biological Chemistry.

[59]  R. Memmott,et al.  The Role of the Akt/mTOR Pathway in Tobacco Carcinogen–Induced Lung Tumorigenesis , 2009, Clinical Cancer Research.

[60]  S. Bao,et al.  The activation of Akt/PKB signaling pathway and cell survival , 2005, Journal of cellular and molecular medicine.

[61]  M. Birnbaum,et al.  Identification of a Proline-rich Akt Substrate as a 14-3-3 Binding Partner* , 2003, The Journal of Biological Chemistry.

[62]  G. Robertson.  Functional and therapeutic significance of Akt deregulation in malignant melanoma , 2005, Cancer and Metastasis Reviews.

[63]  C. MacKintosh,et al.  Differential 14-3-3 Affinity Capture Reveals New Downstream Targets of Phosphatidylinositol 3-Kinase Signaling* , 2009, Molecular & Cellular Proteomics.

[64]  M. Yaffe,et al.  The Structural Basis for 14-3-3:Phosphopeptide Binding Specificity , 1997, Cell.

[65]  Steven P Gygi,et al.  Large-scale characterization of HeLa cell nuclear phosphoproteins. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[66]  John Calvin Reed,et al.  Regulation of cell death protease caspase-9 by phosphorylation. , 1998, Science.

[67]  P. Workman,et al.  Preclinical Pharmacology, Antitumor Activity, and Development of Pharmacodynamic Markers for the Novel, Potent AKT Inhibitor CCT128930 , 2010, Molecular Cancer Therapeutics.

[68]  H. Guan,et al.  Sphingosine Kinase 1 Regulates the Akt/FOXO3a/Bim Pathway and Contributes to Apoptosis Resistance in Glioma Cells , 2011, PloS one.

[69]  S. R. Datta,et al.  Cellular survival: a play in three Akts. , 1999, Genes & development.

[70]  I. Yang,et al.  The molecular genetics and tumor pathogenesis of meningiomas and the future directions of meningioma treatments. , 2011, Neurosurgical focus.

[71]  S. R. Datta,et al.  Akt Phosphorylation of BAD Couples Survival Signals to the Cell-Intrinsic Death Machinery , 1997, Cell.

[72]  Jonathan R. Brestoff,et al.  Rapamycin does not improve insulin sensitivity despite elevated mammalian target of rapamycin complex 1 activity in muscles of ob/ob mice. , 2008, American journal of physiology. Regulatory, integrative and comparative physiology.

[73]  Wenhua Zheng,et al.  Insulin-like growth factor-1-induced phosphorylation of transcription factor FKHRL1 is mediated by phosphatidylinositol 3-kinase/Akt kinase and role of this pathway in insulin-like growth factor-1-induced survival of cultured hippocampal neurons. , 2002, Molecular Pharmacology.

[74]  M. Hung,et al.  Cytoplasmic localization of p21Cip1/WAF1 by Akt-induced phosphorylation in HER-2/neu-overexpressing cells , 2001, Nature Cell Biology.

[75]  P. Hornbeck,et al.  Phosphoprotein Analysis Using Antibodies Broadly Reactive against Phosphorylated Motifs* , 2002, The Journal of Biological Chemistry.

[76]  Toshiyuki Obata,et al.  Peptide and Protein Library Screening Defines Optimal Substrate Motifs for AKT/PKB* , 2000, The Journal of Biological Chemistry.

[77]  G. Robertson,et al.  PRAS40 deregulates apoptosis in malignant melanoma. , 2007, Cancer research.

[78]  Mahlon D. Johnson,et al.  Increased STAT-3 and synchronous activation of Raf-1-MEK-1-MAPK, and phosphatidylinositol 3-Kinase-Akt-mTOR pathways in atypical and anaplastic meningiomas , 2008, Journal of Neuro-Oncology.

[79]  S. Carr,et al.  PRAS40 is an insulin-regulated inhibitor of the mTORC1 protein kinase. , 2007, Molecular cell.

[80]  J. Olefsky,et al.  Protein Phosphatase 2A Negatively Regulates Insulin's Metabolic Signaling Pathway by Inhibiting Akt (Protein Kinase B) Activity in 3T3-L1 Adipocytes , 2004, Molecular and Cellular Biology.

[81]  J. Cheng,et al.  Deregulated Akt3 Activity Promotes Development of Malignant Melanoma , 2004, Cancer Research.

[82]  Huan Yang,et al.  The Akt/PKB pathway: molecular target for cancer drug discovery , 2005, Oncogene.

[83]  M. Yaffe,et al.  A motif-based profile scanning approach for genome-wide prediction of signaling pathways , 2001, Nature Biotechnology.

[84]  P. Sen,et al.  Involvement of the Akt/PKB signaling pathway with disease processes , 2003, Molecular and Cellular Biochemistry.

[85]  Howard L McLeod,et al.  PI3K/Akt/mTOR pathway as a target for cancer therapy , 2005, Anti-cancer drugs.

[86]  J. Woodgett,et al.  PKB/AKT: functional insights from genetic models , 2001, Nature Reviews Molecular Cell Biology.

[87]  D. Meredith,et al.  Extracellular and subcellular regulation of the PI3K/Akt cassette: new mechanisms for controlling insulin and growth factor signalling. , 2007, Biochemical Society transactions.

[88]  Atsushi Saito,et al.  Neuroprotective Role of a Proline-Rich Akt Substrate in Apoptotic Neuronal Cell Death after Stroke: Relationships with Nerve Growth Factor , 2004, The Journal of Neuroscience.

[89]  V. Steele,et al.  Targeting the AKT protein kinase for cancer chemoprevention , 2007, Molecular Cancer Therapeutics.